Komori
Governance4569KYORIN Pharmaceutical Co.,Ltd.Pharmaceuticals

Notice Regarding Partial Revision of the Share-Based Compensation Plan

Executive officers serving under delegation agreements, excluding outside directors, have been added to the eligible participants in the performance-linked stock compensation plan. The annual grant limit has been set at 43,000 points, including 25,000 points for directors.

Worth reading
—
Scored from 0 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
43000
Points / fiscal year
Wording
Definitive
How definitive the wording is.

Contents of this filing

Changes this time

Executive officers serving under delegation agreements have been added to the eligible participants in the performance-linked stock compensation plan. The annual grant limit has been revised to 43,000 points, including 25,000 points for directors.

この書類は、機関設計や取締役会の構成そのものは述べていません。上に示したのは、この書類が述べている変更点です。

Contents of this filing
ItemDetails
Changes this timeExecutive officers serving under delegation agreements have been added to the eligible participants in the performance-linked stock compensation plan. The annual grant limit has been revised to 43,000 points, including 25,000 points for directors.
Items this document does not state (7)
Corporate Governance StructureNumber of directorsNumber of independent officersCommitteePolicy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The reasons include adding the Company's executive officers serving under delegation agreements to the eligible participants. The points limit was determined after comprehensively considering the current level of executive compensation, trends in and future expectations for the number of directors and other officers, and other factors.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Partial Revision of the Share-Based Compensation Plan | KYORIN Pharmaceutical Co.,Ltd. (4569) timely disclosure | Komori